查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198656

移植診斷市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Transplant Diagnostics Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

移植診斷市場預計在預測期內（2022 年至 2027 年）的複合年增長率為 7.8%。

COVID-19 對所調查市場的增長產生了重大影響。 根據一項題為“實體器官移植中 COVID-19 的診斷測試”的研究。 在 2020 年 10 月的“當前臨床應用和未來策略”中，實體器官移植的多個方面受到 COVID-19 流行病的影響，包括供體和受體的適用性、移植後感染和感染預防。我在這裡。 在 COVID-19 大流行期間，對 SARS-CoV-2 在免疫功能低下患者中的診斷保真度和傳染性的了解不斷增加，繼續指導實體器官移植的最佳實踐。 因此，由於在大流行期間與移植相關的挑戰，COVID-19 對市場增長產生了顯著影響。

移植是許多長期接受透析的終末期腎病患者的首選治療方法之一。 在涉及心臟、肝臟和骨髓的病例中，移植也是一種可行的選擇。 此外，隨著公司投資開發更好的 HLA 分型技術、抗體監測、儀器和軟件，診斷技術在過去十年中有了顯著改善。 在體內移植各種器官時，它越來越多地用於診斷目的。

器官捐獻的增加極大地促進了被調查市場的增長。 根據器官獲取組織協會（AOPO）2021 年 1 月發布的數據，2020 年有超過 12,500 人捐獻了一個或多個器官，比上一年增長了 6%。 2020年死者器官捐獻超過3.65萬件，同比增長近2%。 它還報告說，在過去七年中，死者器官挽救了 33,000 多條生命，超過了前一年的總數。 心血管死後捐贈 (DCD) 捐款也顯著增加，2020 年捐贈者超過 3,000 人。 器官捐贈的增加導致對移植診斷測試的需求增加，從而推動了市場的增長。

此外，市場參與者推出新產品也有助於市場的增長。 例如，2021 年 9 月，Thermo Fisher Scientific 在美國組織相容性和免疫遺傳學 (ASHI) 年會上為其移植診斷產品組合增加了兩種新產品。

然而，高移植成本、不規範的保險和報銷政策以及與器官移植相關的社會和倫理問題可能會阻礙預測期內的市場增長。

移植診斷試劑市場趨勢

在預測期內，實體器官移植板塊有望佔據主要份額

在預測期內，實體器官移植領域預計將佔據主要份額。 實體器官移植始於 20 世紀的一種實驗方法，現在被認為是終末期器官功能障礙患者的既定且可行的治療選擇。 大多數移植是針對腎臟進行的，其次是肝臟。

根據衛生資源服務局 2022 年 2 月的數據，美國有超過 106,000 人在實體器官移植的國家移植等待名單上。 等待實體器官移植的人群比例為腎臟（83%）、肝臟（11%）、胰腺（1%）、心臟（3%）和其他（2%）。 預計對實體器官的需求增加將需要增加移植測試，從而在預測期內推動該行業的增長。

此外，器官移植檢測的增加預計將推動這些檢測的採用，從而推動該細分市場的增長。 例如，2021 年 9 月，通過基因檢測和無細胞 DNA (cfDNA) 檢測轉變護理的領先公司之一 Natera Inc. 將推出 Prospera with Quantification，這是一種用於腎臟排斥反應的 cfDNA 檢測。

此外，增加對實體器官移植的資助將進一步促進預測期內所研究市場的增長。 例如，根據美國國立衛生研究院（NIH）2022年5月的數據，2020年和2021年用於器官移植研究的經費分別為2.08億美元和2.01億美元。 由於在研究中越來越多地採用移植診斷，預計對實體器官移植研究的如此高額資助將進一步推動這一領域的增長。

因此，上述因素預計將在預測期內推動該細分市場的增長。

預計在預測期內北美將佔據所研究市場的主要份額

北美佔移植診斷市場的主要份額，預計在預測期內將保持相同的增長速度。

該地區的國家（例如美國和加拿大）擁有完善的資助機構、基礎設施以及政府參與籌集資金和提高意識以促進患者器官移植的能力。 例如，根據美國國立衛生研究院2022年5月的數據，2020年、2021年和2022年（預計）用於移植的研究經費將分別達到7.21億美元、7.02億美元和7.35億美元。 因此，增加對移植研究的資助將導致移植診斷的使用增加，從而推動該地區的市場增長。

此外，根據2022年2月公佈的《器官捐獻統計》，2021年美國進行了4萬多例器官移植。 因此，在預測期內，增加移植將推動該市場的增長。

預計主要市場參與者不斷增加的舉措將有助於市場的進一步增長。 這些公司在用於快速診斷移植前後疾病的新產品的營銷方面取得了進展，並被美國和加拿大的私人和政府機構廣泛接受。 例如，2022 年 3 月，致力於加快評估早期腎臟損傷的生物技術公司 Nephrosant 宣布招募了第一位患者。 將招募多達 2,000 人並觀察 24 個月。 在此期間，QSant 測試和標準診斷程序用於尋找急性排斥反應的證據。 預計這種類型的測試將進一步推動北美移植診斷試劑市場的增長，北美的移植診斷測試正變得越來越普遍。

因此，由於上述因素，北美地區有望在預測期內實現增長。

移植診斷市場競爭者分析

移植診斷市場的競爭是溫和的。 在試劑功效、可負擔性、改善臨床醫生決策和意識以及充足的器官儲存設施方面的技術進步是公司在預測期內必須克服的一些當前機遇和挑戰。它被認為是。 移植診斷市場的主要參與者包括 Abbott Laboratories、Biomerieux SA、F Hoffmann La Roche AG、Qiagen NV、Thermo Fisher Scientific Inc. 等公司。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動力
    • 移植手術增加
    • 移植診斷試劑的技術進展
    • 政府與私營部門合作，為目標疾病的研究提供資金
  • 市場製約因素
    • 移植成本高
    • 保險和報銷政策
    • 與器官移植相關的社會和倫理問題
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按技術
    • 分子
      • 基於 PCR 的分子檢測
      • 基於測序的分子檢測
    • 非分子
  • 按產品分類
    • 設備
    • 試劑
    • 軟件
  • 按移植類型
    • 實體器官
    • 幹細胞
    • 軟組織
  • 通過申請
    • 診斷
    • 調查
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 法國
      • 德國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Biomerieux SA
    • Bio-Rad Laboratories Inc.
    • CareDx
    • F Hoffman-La Roche AG
    • Hologic Inc.
    • Illumina Inc.
    • Qiagen NV
    • Thermo Fisher Scientific Inc.
    • Immucor, Inc.
    • Omixon Ltd.
    • GenDx
    • BioGenuix

第7章 市場機會與今後動向

簡介目錄
Product Code: 67617

The transplant diagnostics market is poised to register a CAGR of 7.8% during the forecast period (2022-2027).

COVID-19 had a significant impact on the growth of the studied market. According to the study titled "Diagnostic Testing of COVID-19 in Solid Organ Transplantation: Current Clinical Application and Future Strategies" in October 2020, multiple elements of solid organ transplantation have been impacted by the COVID-19 pandemic, including donor and recipient appropriateness, as well as infection and transmission prevention following transplantation. During the COVID-19 pandemic, growing knowledge about the diagnostic fidelity and transmissibility of SARS-CoV-2 in immunocompromised patients continued to guide best practices for solid organ transplantation. Thus, owing to the challenges associated with transplantation amid the pandemic, COVID-19 had a pronounced impact on the growth of the market.

Transplantation is one of the preferred treatment options for many patients suffering from end-stage renal disease and undergoing chronic dialysis therapy. Also, transplantation is a viable option considered in cases associated with the heart, liver, and bone marrow. Additionally, in the past decade, diagnostics have improved significantly as companies have been committed to develop better HLA typing technologies, antibody monitoring, instruments, and software. This is gradually being used for diagnostics during the transplantation of different organs of the body.

The rising donation of organs is one of the major contributors to the growth of the studied market. According to the data published by the Association of Organ Procurement Organizations (AOPO) in January 2021, more than 12,500 people donated one or more organs in 2020, up 6% from the previous year. The number of organs donated from dead donors increased to over 36,500 in 2020, which is almost a 2% increase year over year. It also reported that in the past seven years, organs from the dead have saved more than 33,000 lives, exceeding the previous year's totals. There were also notable increases in donations after circulatory death (DCD) contributions, which totaled more than 3,000 donors in 2020. The rise in organ donation creates the need for increased transplant diagnostic testing and thus drives the growth of the market.

Moreover, the launch of new products by the market players also contributes to the growth of the market. For instance, in September 2021, Thermo Fisher Scientific added two new products to its transplant diagnostics portfolio during the American Society for Histocompatibility and Immunogenetics (ASHI) annual conference.

However, the high cost of transplants, irregular insurance and reimbursement policies, and social and ethical issues related to organ transplants may hinder the growth of the market over the forecast period.

Transplant Diagnostics Market Trends

Solid Organ Transplant Segment is Expected to Hold a Major Share over the Forecast Period

The solid organ transplant segment is expected to hold a major share over the forecast period. Solid-organ transplantation was started as an experimental approach in the 20th century and is now considered a well-established and practical treatment option for patients suffering from end-stage organ dysfunction. The majority of transplants are done for kidneys, followed by the liver.

According to the Health Resources and Services Administration in February 2022, there are over 106,000 people on the national transplant waiting list for solid organ transplantation in the United States. The percentage of people waiting for solid organ transplants includes the kidney (83%), liver (11%), pancreas (1%), heart (3%), and others (2%). The rise in demand for solid organs creates a need for increased testing for transplantation, which is expected to drive the growth of the segment over the forecast period.

In addition, the rising number of organ transplant tests will also drive the growth of this segment due to the rise in the adoption of these tests. For instance, in September 2021, Natera Inc., one of the key players in transforming care through genetic and cell-free DNA (cfDNA) testing, launched Prospera with Quantification, the cfDNA test for kidney rejection.

Moreover, rising funding for solid organ transplantation will further contribute to the growth of the market studied over the forecast period. For instance, according to the National Institutes of Health (NIH) in May 2022, the funding for organ transplant research in 2020 and 2021 was USD 208 million and USD 201 million, respectively. Such high funding for solid organ transplant research will drive the growth of this segment further due to the rise in the adoption of transplant diagnostics in research.

Therefore, owing to the above-mentioned factors, this segment's growth is expected to drive over the forecast period.

North America is Expected to Hold a Major Share in the Studied Market Over the Forecast Period

North America is expected to hold a major share in the transplant diagnostics market and is expected to continue at the same pace over the forecast period.

Countries of the region such as the United States and Canada are well-equipped with the funded organizations, infrastructure, and government participation in raising funds and awareness to promote the transplantation of organs for patients. For instance, according to the National Institute of Health in May 2022, the funding for research in transplantation was USD 721 million, USD 702 million, and USD 735 million in 2020, 2021, and 2022 (estimated) respectively. The rise in funding for transplantation research will therefore lead to increased utilization of transplant diagnostics and drive the growth of the market in this region.

In addition, according to the Organ Donation Statistics published in February 2022, more than 40,000 organ transplantations took place in the United States in 2021. The rise in transplantations will therefore drive the growth of this market over the forecast period.

Rising initiatives from the key market players are expected to contribute to the market's growth further. These companies are advanced in marketing new products for faster diagnostics of diseases before and after the transplants, which are well accepted by the private organizations and governments of the United States and Canada. For instance, in March 2022, NephroSant, a biotechnology firm devoted to speeding up the assessment of early kidney damage, recruited the first patient in the Evaluation of QSant for Underlying Allograft Rejection (AQUA) study. Up to 2,000 people will be enrolled and observed for 24 months, during which time QSant testing and standard-of-care diagnostics will be used to look for evidence of acute rejection. This type of trial will further boost the market growth of transplant diagnostics in North America due to the greater adoption of transplant diagnostic tests.

Thus, owing to the abovementioned factors, the North American region is expected to project growth over the forecast period.

Transplant Diagnostics Market Competitor Analysis

The market for transplant diagnostics is moderately competitive. The technological advancements, in terms of reagent effectiveness, affordability, clinicians' decision-making and raising awareness, and proper organ preservation facilities, are some of the present-day opportunities and challenges that the companies are expected to overcome during the forecast period. Some of the major companies expanding in the transplant diagnostics market include Abbott Laboratories, Biomerieux SA, F Hoffmann La Roche AG, Qiagen NV, and Thermo Fisher Scientific Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Transplant Procedures
    • 4.2.2 Technological Advacements in Transplant Diagnostics
    • 4.2.3 Government and Private Collaboration into Funding Research of Target Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Transplant
    • 4.3.2 Insurance and Reimbursement Policies
    • 4.3.3 Social and Ethical Issues Related to Organ Transplant
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Technology
    • 5.1.1 Molecular
      • 5.1.1.1 PCR-based Molecular Assays
      • 5.1.1.2 Sequencing-based Molecular Assays
    • 5.1.2 Non-molecular
  • 5.2 By Product
    • 5.2.1 Instrument
    • 5.2.2 Reagent
    • 5.2.3 Software
  • 5.3 By Transplant Type
    • 5.3.1 Solid Organ
    • 5.3.2 Stem Cell
    • 5.3.3 Soft Tissue
  • 5.4 By Application
    • 5.4.1 Diagnostic
    • 5.4.2 Research
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 France
      • 5.5.2.2 Germany
      • 5.5.2.3 United Kingdom
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Biomerieux SA
    • 6.1.4 Bio-Rad Laboratories Inc.
    • 6.1.5 CareDx
    • 6.1.6 F Hoffman-La Roche AG
    • 6.1.7 Hologic Inc.
    • 6.1.8 Illumina Inc.
    • 6.1.9 Qiagen NV
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 Immucor, Inc.
    • 6.1.12 Omixon Ltd.
    • 6.1.13 GenDx
    • 6.1.14 BioGenuix

7 MARKET OPPORTUNITIES AND FUTURE TRENDS